Product Details

Face2Gene LABS – Listing

The customer’s logo will appear in the Listed Labs section of Face2Gene CLINIC and link to FDNA-approved customer information. The customer’s logo will also be highlighted in FDNA sponsored Listed Labs Campaigns. Listed Labs Campaigns are designed by FDNA and customer display within the campaign is limited to a name and logo image, linking to an FDNA-approved customer landing page. 

 

Face2Gene LABS – Requisition

There is no limit to the number of cases that can be processed using this product, and there is no additional charge for HPO term extraction. Use of NGP analyses for NGS tests are not included in the base product cost and will incur an additional $50/case charge.

 

Face2Gene LABS – NGS Analysis

Product tiers include set case analysis quantities: 

  • Bronze 40/month
  • Silver 80/month
  • Gold 145/month
  • Platinum 300/month

Additional case analysis is billed at a $50/case rate when the customer’s tier case analysis quantity is surpassed. The customer may upgrade to a higher product tier mid-term and the product cost will be prorated for the remainder of the proposal term.

 

Face2Gene LABS – Bundle

Product tiers include set case analysis quantities: 

  • Bronze 40/month
  • Silver 80/month
  • Gold 145/month
  • Platinum 300/month

Additional case analysis is billed at a $40/case rate when the customer’s tier case analysis quantity is surpassed. The customer may upgrade to a higher product tier mid-term and the product cost will be prorated for the remainder of the proposal term. NGS case total is calculated as the sum of cases shared by end-users through Face2Gene combined with the number of cases shared via Requisition and embedded FDNA solutions.

 

Face2Gene Campaigns

Cost is a function of exposure and is assessed based on end-user views. Views are assessed every 30 days beginning with the go-live date. Multiple views by the same end-user within the same 30-day-cycle are considered a single view. The number of end-users outlined on the proposal represents 80% of the target audience as mutually agreed upon. This product includes a weekly end-user view report service. Customer Campaign content can be updated on a monthly basis. All Campaign ad content and design must meet the FDNA media kit requirements and be received 15 days prior to go-live date. FDNA reserves the right to review and approve or deny customer Campaign content at any time. In the event FDNA denies a Campaign, FDNA will provide a clear timeline and requirements needed to post the updated Campaign. Amount listed on this proposal is the base monthly cost and is due prior to the go-live date. Fees for additional views are assessed and invoiced at the end of every 30-day-cycle. 

 

Face2Gene LIBRARY

Subscription access requires a Face2Gene account. The subscription is initiated after receipt of payment. Invoicing is available for annual subscriptions only. Network subscription access is limited to one email domain and/or a list of Face2Gene usernames provided by the network administrator. Domain access is not available for broadly used domains, for example domains used by national health systems. In these instances, a userlist is required. A network userlist can be updated at any time by emailing requests to library@fdna.com.

 

Last updated: February 24, 2020

 

Face2Gene User Community Includes Users From:

  • Using Face2Gene to reference all my department’s cases, share information with my colleagues and quickly look up relevant information in the London Medical Databases Online saves me hours of work every week and allows me to focus on my patients.

    Dr. Ibrahim Akalin

    Assoc. Prof. Ibrahim Akalin, MD, Medical Geneticist from the Istanbul Medeniyet University, Istanbul, Turkey

  • FDNA’s game-changing technology introduces an objective computer-aided dimension to the “art of dysmorphology”, transforming the analysis into an evidence-based science.

    Dr. Michael R. Hayden

    Chairman of FDNA’s Scientific Advisory Board & Steering Committee and Editor in Chief of Clinical Genetics

  • FDNA is developing technology that has the potential to help so many physicians and families by bringing them closer to a diagnosis- there are literally millions of individuals with unusual features around the world that lack a diagnosis and therefore lack information on natural history, recurrence risk and prevention of known complications.

    Dr. Judith G. Hall

    Professor Emerita of Pediatrics & Medical Genetics UBC & Children's and Women's Health Centre of BC

  • FDNA has been “right on the money”, providing me with relevant, accurate and insightful information for differential diagnoses.

    Dr. Cynthia J.R. Curry

    Professor of Pediatrics UCSF, Adjunct Professor of Pediatrics Stanford

  • I am excited to be a part of the FDNA community, promoting broad information sharing with my peers to amplify the scientific and clinical value of our community’s accumulated knowledge for the purpose of efficiently diagnosing individuals with rare genetic disorders.

    Dr. Karen W. Gripp

    Chief, Division of Medical Genetics A.I. duPont Hospital for Children

  • FDNA's idea of incorporating several dysmorphology resources (OMIM, GeneReviews), supported by their visual analytic technology, will be able to improve researching of genetic syndromes - all within a single mobile app.

    Dr. Chad Haldeman-Englert

    Assistant Professor Pediatrics at Mission Fullerton Genetics

  • Given the advancement of visual analytical technology, it’s about time Dysmorphology is supported with computational capabilities and moving this to mobile support, is simply the next logical step.

    Dr. Chanika Phornphutkul

    Associate Professor of Pediatrics Director, Division of Human Genetics Department of Pediatrics Warren Alpert Medical School of Brown University

  • Having an archive of cases easily accessible from my mobile device anytime and anywhere is a long-time unmet need.

    Dr. Lynne Bird

    Rady Children's Specialists of San Diego

  • FDNA's solution is a huge leap forward for dysmorphology. It saves me significant time when I’m evaluating patients in my clinic and provides me with insightful tools that help me generate a differential diagnosis.

    Dr. David A. Chitayat

    Head of the Prenatal Diagnosis and Medical Genetics Program at Mount Sinai Hospital, Toronto

  • Shortly after learning about Face2Gene, I’ve started to incorporate this amazing tool into my workflow. Soon enough, Face2Gene’s analysis flushed out references that I would not have considered for several of my patients, which turned out to be their correct diagnosis

    Dr. Zvi U. Borochowitz

    Chairman (Retired) of The Simon Winter Institute for Human Genetics at Bnai-Zion Medical Center, Technion-Rappaport Faculty of Medicine

  • The Unknown Forum from Face2Gene is a great community platform for exchanging opinions regarding undiagnosed cases. It is straightforward to use and safe for exchange of medical data, thanks to the efforts of its developers and to the involvement of geneticists worldwide.

    Dr. Oana Moldovan

    Clinical Geneticist at the Hospital Santa Maria, CHLN, Lisbon, Portugal